Peter J. Darlington

Inhibition of CTLA-4 function by the regulatory subunit of serine/threonine phosphatase 2A.

Surface cytotoxic T lymphocyte-associated antigen 4 partitions within lipid rafts and relocates to the immunological synapse under conditions of inhibition of T cell activation.

Hierarchical regulation of CTLA-4 dimer-based lattice formation and its biological relevance for T cell inactivation.

Widespread immunoreactivity for neuronal nuclei in cultured human and rodent astrocytes.

Innate immune-mediated neuronal injury consequent to loss of astrocytes.

Modulation of T cell activation by stomatin-like protein 2.

Emerging multiple sclerosis disease-modifying therapies.

Fingolimod (FTY720) enhances remyelination following demyelination of organotypic cerebellar slices.

Abnormal B-cell cytokine responses a trigger of T-cell-mediated disease in MS?

Reciprocal Th1 and Th17 regulation by mesenchymal stem cells: Implication for multiple sclerosis.

Response of human oligodendrocyte progenitors to growth factors and axon signals.

TLR2 stimulation drives human naive and effector regulatory T cells into a Th17-like phenotype with reduced suppressive function.

Harnessing the therapeutic potential of mesenchymal stem cells in multiple sclerosis.

Neurite outgrowth is differentially impacted by distinct immune cell subsets.

Diminished Th17 (not Th1) responses underlie multiple sclerosis disease abrogation after hematopoietic stem cell transplantation.